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nucleotide polymorphism (SNP) discovered in the meth-
ylenetetrahydrofolate reductase (MTHFR) gene (Van der
Put et al. 1998). We agree that the numbering that was
used may be confusing for two reasons.
First, we designated this SNP as the “1298(ArC)
mutation,” by use of the same numbering method
used to indicate the 677(CrT) substitution, the first
SNP discovered in the MTHFR gene (Frosst et al.
1995). Although this SNP is designated to be at po-
sition 677, the actual location of this SNP may be at
position 665 of the coding region, if numbering is
started at the first ATG site of the reported coding
sequence (Goyette et al. 1994). Thus, discrepancies in
numbering started before the discovery of the second
SNP. We therefore had two options for determining
the nomenclature of the second SNP in the MTHFR
gene: either to start numbering at the ATG or to use
the method of numbering that is in concordance with
that used for the first SNP. In our opinion, this last
option would be more reasonable, because of the
widely accepted nomenclature of the 677(CrT) sub-
stitution. Therefore, we designated the second SNP as
the “1298(ArC) mutation.”
Second, the sequence reported by Goyette et al. (1994)
unfortunately contained a C at the 1298 sequence, in-
stead of at the much more common 1298A sequence, of
the MTHFR gene. We have no doubt that the mutation
is an ArC, rather than a CrA, transition, which is
clearly reflected by the prevalence of the 1298 SNP and
its effect on MTHFR activity (van der Put et al. 1998).
Additionally, we would like to describe an improved
method of PCR/RFLP screening for the 1298 SNP. By
use of two PCR primers—forward primer ATGTGG-
GGGGAGGAGCTGAC and the intronic reverse primer
GTCTCCCAACTTACCCTTCTCCC—a 241-bp frag-
ment will be obtained. If the wild-type genotype
(1298AA) is present, then the MboII RFLP results in
two fragments—one that is 204 bp and one that is 37
bp. For the homozygous mutated MTHFR genotype
(1298CC), only the 241-bp fragment is obtained, and,
for the heterozygous genotype, all three fragments are
obtained. These RFLP fragments can be easily differ-
entiated by means of agarose-gel electrophoresis.
We examined the possible interference of the
1317(TrC) transition with the proper screening of the
1298 SNP. 1317(TrC) is a silent mutation (Weisberg
et al. 1998) that, like the 1298 SNP, results in the
formation of an MboII recognition site and that could
thus disturb genotyping of 1298. We performed re-
striction-enzyme analysis with MboII and BpuAI—
the latter restriction enzyme recognizes only the
1317(TrC) substitution—on the PCR-obtained 241-
bp fragment and looked for possible misinterpretation
of the 1298 genotype. The 1317CC genotype was not
observed among 450 Dutch individuals, and we ob-
served only 3 heterozygous individuals, which re-
sulted in the 1317C allele having a frequency of .003
among the Dutch population. The 1317 SNP did not
interfere with the proper genotyping of 1298; in all
three cases, the 1317C allele was present on a 1298A
allele, which already results in a MboII recognition
site. Possibly, the 1317C substitution arose at the
1298A allele and, thus, will not disturb genotyping
of 1298.
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Special Oversight Groups to Add Protections for
Population-Based Repository Samples
To the Editor:
The National Institute of General Medical Sciences
(NIGMS) supports the Human Genetic Cell Repository
through a contract to the Coriell Institute for Medical
Research in Camden, NJ. The repository supplies cell
lines and DNA samples to investigators worldwide. Al-
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though most of the 6,300 cell lines in the repository are
derived from individuals with genetic disorders or from
their family members, others in the repository were ac-
quired because they represent distinct, identified popu-
lations. Designated as the Human Variation Collection,
these samples come from anonymous, unrelated indi-
viduals and have no phenotypic information associated
with them. In recent years, researchers have shown a
growing interest in studying these samples (1) to answer
fundamental questions related to genetic architecture of
complex traits, (2) to distinguish between a disease-caus-
ing mutation and a normal polymorphism, and (3) to
identify genes in rare and common disorders. This in-
terest has prompted the genetics research community to
ask the repository to acquire samples from additional
identified populations. At the same time, members of
some populations and some bioethicists have raised con-
cerns about possible negative consequences (such as ster-
eotyping, stigmatization, discrimination, and commu-
nity disruption) to a population resulting from genetic
studies on identified populations.
NIGMS recently held a workshop (Workshop on Pop-
ulation-Based Samples for the NIGMS Human Genetic
Cell Repository) to consider the scientific benefits and
the risks to populations of expanding the collection of
such samples and to develop recommendations about
whether, and under what conditions, the repository
should acquire these samples. A key set of recommen-
dations describes a novel approach to increase the pro-
tection of populations, and it is the purpose of this letter
both to inform the human genetics research community
about these recommendations and to encourage further
discussion about the means to protect populations in
genetics research. In parallel, additional input from
members of diverse populations is being sought.
Federal regulations (Title 45, Code of Federal Regu-
lations, Part 46) focus on the protection of individuals
and do not extend protections to populations or other
groups. The recommendations of the Workshop on Pop-
ulation-Based Samples for the NIGMS Human Genetic
Cell Repository were designed to complement the federal
regulations by establishing an Oversight Group for Pop-
ulation-Based Samples (OGPBS) that would assure that
samples were (or will be) acquired with due protection
of the population from which samples are collected. As
detailed in the report of the Workshop on Population-
Based Samples for the NIGMS Human Genetic Cell Re-
pository, each population-specific OGPBS would specify
criteria for consultation with and participation by mem-
bers of the population; for informing the population and
individual sample donors about the use of the samples,
the benefits, if any, that are promised, the potential harm
to the population, and what will be done to minimize
harm; and for the documentation about these activities
required from investigators who collect samples for sub-
mission to the repository.
An alternative to the OGPBS model would be for in-
stitutional review boards (IRBs) to be more vigilant in
their protection of populations. There are several ad-
vantages, however, to using an OGPBS for this purpose.
First, it is unlikely that an IRB would have the expertise
that could be assembled in an OGPBS, particularly that
provided by members of the population under consid-
eration. Second, investigators who will collect samples
for submission to the repository will come from different
institutions, with different IRBs. Greater continuity can
be achieved by the ability to coordinate the OGPBS, for
example, by having some members participate in several
groups. And third, it is expected that oversight will be
ongoing during the entire process of sample collection,
acquisition by the repository, distribution, and genera-
tion of research results. Only a group constituted spe-
cifically for this purpose is likely to provide the appro-
priate level of protection over an extended period of
time, and, specifically, beyond the period of review by
an IRB, which would end with the collection of the
samples.
Some populations might consider these protections in-
adequate, and some investigators might consider them
too onerous. However, the concept behind the OGPBS
model is that it provides a flexible approach to main-
taining high standards for the protection of diverse
populations with different concerns while attempting to
provide a valuable genetic resource to the research com-
munity. It is hoped that the proposed establishment of
OGPBS and the outline of proposed protections will pro-
mote discussion of these recommendations or alterna-
tives by the genetics and bioethics communities and by
the populations that will be the potential sources of sam-
ples and the partners in this valuable research resource.
JUDITH H. GREENBERG
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Table 1
Corresponding Members of the International Federation of
Human Genetics Societies
Name of Society Representative
American College of Medical Genetics R. Rodney Howell
Argentina Society of Medical Genetics Susana Turyk
Austrian Society for Human Genetics Gerd Utermann
Brazilian Clinical Genetics Society Joao Monteiro de Pina-Neto
British Society for Human Genetics Andrew Read
Canadian College of Medical Genetics Jane Evans
Czech Society of Medical Genetics Jiri Santavy
Finnish Society of Medical Genetics Minna Poyhonen
French Society of Human Genetics Roland Berger
German Society for Human Genetics Jorg Schmidtke
Hellenic Society of Medical Genetics Micchael Petersen
Hungarian Society of Human Genetics Gyorgy Kosztolanyi
Indian Society of Human Genetics Kiran Kucheria
Irish Society of Human Genetics Nollaig Parfrey
Israeli Society of Medical Geneticists Zvi Borochowitz
Italian Society of Human Genetics Bruno Dallapiccola
Japanese Society of Human Genetics Keiya Tada
Korean Society of Human Genetics Ho Suk Saw
Latvian Medical Genetics Society Rita Lugovska
Lithuanian Society of Human Genetics Vaidutis Kucinskas
Mexican Association of Human Genetics Jose Maria Cantu
Netherlands Society of Human Genetics Gerd-Jan van Ommen
Norwegian Society of Medical Genetics Trond Leren
Polish Society of Human Genetics Jerzy Nowak
Portuguese Society of Human Genetics Carolino Monteiro
Romanian Society of Human Genetics Covic Mircea
Russian Society of Human Genetics Evgeny Ginter
Serbian Society for Human Genetics Miroslava Micic
South African Society for Human Genetics Arnold Christianson
Spanish Association of Human Genetics Alberto Valiente
Swedish Society of Human Genetics Ulf Kristoffersson
Swiss Society of Medical Genetics Daniel Schorderet
Turkish Association of Medical Genetics Memnune Apak
Genetics Society of Vietnam Le Dinh Luong
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Letter to Human Genetics Journals
To the Editor:
The International Federation of Human Genetics Soci-
eties (IFHGS) was founded in 1996. This report was
written to inform the international community of human
geneticists of the history, purpose, and structure of the
organization.
The IFHGS was founded to provide a transparent
structure to facilitate communication throughout the
international community of human geneticists. The
IFHGS, still in its infancy, serves its constituent mem-
bers—human genetics societies around the world—by
providing a platform to share, interactively, information
about research, education, and clinical services. The by-
laws of the Federation state that “the purpose of The
International Federation of Human Genetics Societies
(the Federation) is to provide a forum for organized
groups dedicated to all aspects of human genetics, in-
cluding research, clinical practice, and professional and
lay education. The Federation will enable communica-
tion between its member groups and encourage inter-
action between workers in genetics fields and in related
sciences and will make itself available to promote meet-
ings and publications and other forums which support
human genetics research and practice.”
The IFHGS presently has two levels of membership:
full members and corresponding members. The three
founding multinational societies, which are full mem-
bers, are The American Society of Human Genetics
(ASHG), The European Society of Human Genetics
(ESHG), and TheHumanGenetics Society of Australasia
(HGSA).
As new multinational or regional societies are formed,
they may apply to the IFHGS for full-member status.
Two regional societies—the Latin American Society and
the East-Asian Society—are candidates for full mem-
bership. Representatives of full-member societies con-
stitute the Executive Committee. The representatives’
costs for participation in IFHGS activities are borne by
the societies that they represent, and, as currently or-
ganized, the IFHGS does not require a budget or paid
administrative staff.
National human genetics societies are eligible to par-
ticipate in the IFHGS as corresponding members. All
participating individuals, whether from full- or corre-
sponding-member societies, are elected officers or long-
term representative appointees of the constituent human
genetics societies. Any geneticist in the world who is a
member of an affiliated human genetics society is au-
tomatically connected to the IFHGS.
The 34 national human genetics societies that are pres-
ently corresponding members of the IFHGS are listed in
table 1.
At the Ninth International Congress of Human Ge-
netics in Brazil, representatives of the IFHGS met and
decided to undertake the organization and support of
future international congresses of human genetics. The
IFHGS offered to subsume the annual meetings of full-
member societies into these congresses so as to guarantee
high attendance by avoiding any competition with other
annual meetings. This idea was proposed to the leaders
of the Permanent Committee of the International Con-
gresses of Human Genetics, which then selected the Eu-
ropean Society of Human Genetics as the host of the
Tenth International Congress of Human Genetics, which
is to be held in Vienna on May 16–19, 2001. Future
